[
  {
    "vignette_index": 35,
    "input": "Psychotic disorder, likely substance-induced (or brief psychotic disorder) END",
    "output": "THINKING: STEP 1 - DIAGNOSIS CONFIRMATION & SEVERITY ASSESSMENT: - The primary diagnosis is a psychotic disorder likely substance-induced, with points toward stimulant dependence, specifically amphetamine/methamphetamine, in sustained partial remission. The patient's symptoms of perceptual disturbances, paranoia, agitation, sleep disturbances, and emotional lability suggest a severe psychotic episode but with underlying substance use rather than a primary psychotic disorder solely. The severity appears severe given the presence of hallucinations, paranoia, agitation, and risk factors such as emotional instability and potential harm. Urgent care is warranted to ensure safety and stabilization. Monitoring for escalation of symptoms and risk of harm is necessary.  STEP 2 - EVIDENCE-BASED TREATMENT SELECTION: - First-line treatment involves a combination of pharmacotherapy to address psychotic symptoms and substance use management, along with supportive psychosocial interventions. - Supportive pharmacotherapy with antipsychotics is standard, especially to manage psychotic features. - Addressing substance dependence with motivational interviewing and contingency management enhances outcomes. - Caution should be taken with medications in substance-dependent patients due to potential interactions and stimulant toxicity.  STEP 3 - PHARMACOLOGICAL INTERVENTIONS: - Primary medication choice: Atypical antipsychotic such as risperidone 1-2 mg once daily, titrated as needed. - Rationale: Risperidone effectively manages psychotic symptoms with a tolerable side effect profile relevant for agitation and paranoia. - Timeline for improvement: Some symptom reduction can be expected within 1-2 weeks, with ongoing assessment for optimal dosing. - Monitoring: Watch for extrapyramidal symptoms, metabolic side effects, and worsening agitation or sedation. - Alternatives: Olanzapine or aripiprazole if risperidone is poorly tolerated or ineffective.  STEP 4 - NON-PHARMACOLOGICAL INTERVENTIONS: - Primary interventions: Psychoeducation about substance use and psychosis, safety planning, and supportive therapy. - Patient education priorities: Importance of abstinence, recognizing early warning signs, and adherence to medication. - Lifestyle modifications: Regular sleep schedule, nutrition, stress reduction techniques, and avoiding stimuli that trigger paranoia or agitation. - Behavioral interventions: Referral to cognitive-behavioral therapy for psychosis and substance use counseling; consider inpatient stabilization if safety is compromised.  STEP 5 - MONITORING & FOLLOW-UP STRATEGY: - Follow-up timeline: Reassess in 1-2 weeks to evaluate medication response, symptom severity, and safety. - Monitoring parameters: Symptom progression, medication side effects, substance use status, safety risks. - Red flag symptoms: Sudden worsening of hallucinations, suicidality, aggression, or self-harm warrants immediate evaluation. - Treatment response assessment: Use standardized scales (e.g., PANSS) and patient report to gauge improvement.  STEP 6 - PATIENT COMMUNICATION STRATEGY: - Communication approach: Use clear, simple language, avoiding overwhelming detail; prioritize reassurance and collaborative planning. - Addressing concerns: Recognize patient's possible minimization of symptoms, validate feelings, and emphasize safety. - Adherence strategies: Simplify medication regimens, involve support networks, and provide written summaries. - Family involvement: If feasible and with consent, involve trusted family members or caregivers for support and monitoring.  STEP 7 - COORDINATION & REFERRALS: - Specialist referrals: Psychiatry for ongoing management and medication oversight within 24-48 hours. - Other team members: Consider addiction specialists or therapists experienced in substance-induced psychosis. - Community resources: Substance use support groups, mental health outreach, and crisis intervention services. - Insurance/cost considerations: Verify coverage for medications and therapy; explore low-cost or sliding scale options.\nANSWER: Based on the diagnosis of a substance-induced psychotic disorder primarily related to stimulant dependence, I recommend a comprehensive treatment approach that combines evidence-based medical management with patient-centered care strategies. The treatment plan includes initiating an atypical antipsychotic such as risperidone for symptom control, alongside psychosocial interventions like psychoeducation, motivational interviewing, and substance use counseling, tailored to the patient's individual needs. Immediate management focuses on ensuring safety, stabilization, and establishing a supportive therapeutic environment, while long-term management emphasizes ongoing psychiatric care, substance abstinence, and relapse prevention. Follow-up will occur within 1-2 weeks to assess treatment response and safety, with ongoing monitoring and adjustments as needed. This approach aims to reduce psychotic symptoms, support substance recovery, and enhance overall functioning, while minimizing side effects and risks associated with pharmacotherapy.  IMPLEMENTATION GUIDANCE: - Immediate actions (today): Initiate risperidone 1 mg at bedtime for psychotic symptoms; conduct safety assessment; arrange psychiatric follow-up within 48 hours. - Short-term goals (1-4 weeks): Achieve symptom stabilization, monitor side effects, support substance abstinence, and initiate psychoeducation. - Long-term objectives (3-6 months): Maintain remission of psychosis, sustain abstinence, develop coping skills, and evaluate medication necessity for chronic management. - Patient handout summary: Emphasize importance of medication adherence, avoiding substance use, recognizing warning signs, and attending scheduled follow-ups.",
    "gold_diagnosis": "Stimulant dependence including amphetamines, methamphetamine or methcathinone, sustained partial remission"
  }
]